By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

BioMarin Pharmaceutical Inc. 

105 Digital Drive

Novato  California  94949  U.S.A.
Phone: 415-506-6700 Fax: 415-382-7427


SEARCH JOBS

BioMarin leads the biotechnology industry in delivering therapies for chronic and degenerative genetic conditions that reduce patients' quality of life and shorten life spans. We target diseases that lack effective therapies and affect relatively small numbers of patients, many of whom are children. BioMarin continues to focus on advancing therapies that are the first or best of their kind and make a big difference in improving patients' lives.

BioMarin offers a friendly, fast-paced, collegial environment where success is measured by both the individual and collective efforts of hundreds of talented scientists, business professionals, technical specialists and experts in a variety of fields from sales and marketing, to finance, to manufacturing, to clinical and regulatory operations.

BioMarin is growing rapidly to support the development and global commercialization of breakthrough drugs to treat rare genetic diseases. The company’s product portfolio comprises five approved products and multiple clinical and pre-clinical product candidates.

You can make it happen at BioMarin, where the unique combination of big-company success in a small-company environment provides unparalleled opportunity for individual contributions and growth.


Key Statistics


Email: ir@bmrn.com
Ownership: Public

Web Site: BioMarin
Employees: 358
Symbol: BMRN
 









Company News
Bay Area’s BioMarin (BMRN) Expands With The World's “First and Largest” Gene Therapy Manufacturing Plant 8/8/2017 9:36:20 AM
BioMarin (BMRN) Announces Offering Of $450 Million Of Senior Subordinated Convertible Notes Due 2024 8/8/2017 9:18:29 AM
BioMarin (BMRN) Announces Second Quarter 2017 Financial Results 8/3/2017 12:18:45 PM
BioMarin (BMRN) Announces Plans To Progress Both The 6e13vg/Kg And 4e13 Vg/Kg Doses Of BMN 270, Its Investigational Gene Therapy For Hemophilia A, Into Phase III Studies 8/3/2017 8:18:21 AM
BioMarin (BMRN) To Host Second Quarter 2017 Financial Results Conference Call And Webcast On Wednesday, August 2 At 4:30pm ET 8/1/2017 2:02:16 PM
BioMarin (BMRN) To Host Second Quarter 2017 Financial Results Conference Call And Webcast On Wednesday, August 2 At 4:30pm ET 7/19/2017 9:29:20 AM
Sarepta (SRPT) And BioMarin (BMRN) Announce Execution Of A Global Settlement And A License Agreement Resolving Exon Skipping Patent Litigation 7/18/2017 6:39:00 AM
BioMarin (BMRN)'s Investigational Gene Therapy For Hemophilia A At 6e13 Vg/Kg Dose Maintains Average Factor VIII Levels Within Normal Range For Over One Year 7/11/2017 6:42:07 AM
BioMarin (BMRN) Submits Pegvaliase Biologics License Application (BLA) To The U.S. FDA For Treatment Of Phenylketonuria (PKU) 6/30/2017 8:11:18 AM
BioMarin (BMRN) Announces Acceptance Of Late Breaking Abstract At The International Society On Thrombosis And Haemostasis 2017 Congress 6/16/2017 8:40:43 AM
12345678910...
//-->